Charles Sternberg, Associate Editor05.10.22
The Mediliant Group has announced Matt Burba as its new CEO. The new leadership role of Burba is an important factor in the group’s expansion.
Burba came to the Mediliant Group as the top candidate for the CEO position through the group’s main shareholder, Ekkio Capital. Based in Paris, Ekkio Capital is an investment fund which is dedicated to the healthcare market segment. It is committed to accelerating the development of the company with a long-term perspective in mind.
“We are proud to welcome Matt Burba as CEO of the Mediliant Group. His background and success will be key to achieving our goals for Mediliant over the coming years,” said Jean-Marc Sceo, president Ekkio Capital.
With over 18 years of leadership experience in the medical contract manufacturing market, Burba brings to the Mediliant Group a wide range of skills and discipline that will further strengthen the leadership team. Burba is a well-known and respected expert in the industry with a proven track record of leadership, sales growth through Mergers and Acquisitions, and organic development through his high performance in prioritizing customer needs.
"I'm excited to join Mediliant as we grow into a leading global player in the Spine, Trauma, and Extremities contract manufacturing market. We have built a strong platform and expect to accelerate our strategy of creating partnerships to deliver high quality, complex implant solutions with unparalleled customer service. We will continue to add best-in-class companies that provide new and interesting technical capabilities, technologies, and geographies in order to be able to better serve our customers," Burba commented.
The Mediliant Group has strategic growth plans that will focus on speed and helping customers get their products first to market. As the organization broadens, it strives to constantly improve velocity on the shop floor, aiming to be the most responsive partner for its customers. With new leadership, the group will be applying lean thinking to its processes and expects to engage every team member into the continuous improvement journey that will create more flexibility and increased capacity while becoming more efficient.
Burba came to the Mediliant Group as the top candidate for the CEO position through the group’s main shareholder, Ekkio Capital. Based in Paris, Ekkio Capital is an investment fund which is dedicated to the healthcare market segment. It is committed to accelerating the development of the company with a long-term perspective in mind.
“We are proud to welcome Matt Burba as CEO of the Mediliant Group. His background and success will be key to achieving our goals for Mediliant over the coming years,” said Jean-Marc Sceo, president Ekkio Capital.
With over 18 years of leadership experience in the medical contract manufacturing market, Burba brings to the Mediliant Group a wide range of skills and discipline that will further strengthen the leadership team. Burba is a well-known and respected expert in the industry with a proven track record of leadership, sales growth through Mergers and Acquisitions, and organic development through his high performance in prioritizing customer needs.
"I'm excited to join Mediliant as we grow into a leading global player in the Spine, Trauma, and Extremities contract manufacturing market. We have built a strong platform and expect to accelerate our strategy of creating partnerships to deliver high quality, complex implant solutions with unparalleled customer service. We will continue to add best-in-class companies that provide new and interesting technical capabilities, technologies, and geographies in order to be able to better serve our customers," Burba commented.
The Mediliant Group has strategic growth plans that will focus on speed and helping customers get their products first to market. As the organization broadens, it strives to constantly improve velocity on the shop floor, aiming to be the most responsive partner for its customers. With new leadership, the group will be applying lean thinking to its processes and expects to engage every team member into the continuous improvement journey that will create more flexibility and increased capacity while becoming more efficient.
